Shelter Pharma share news, announcements and annual reports
BSE: 543963Pharmaceuticals & BiotechnologySmall Cap
SHELTER PHARMA LIMITED · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Aug 2023
Last close ₹39.60down ₹2.06 (4.94%)
Share price at the BSE close on 28 Oct 2026. Previous close ₹41.66.
28 Oct: open ₹39.71, high ₹39.71, low ₹39.60
52-week range of traded prices to 28 Oct 2026
₹23.00Low, 9 Jul 2026₹55.88High, 13 Oct 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹69 Cr3,366th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 7.59
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 0.89
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 15.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.01
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 24,000
Shelter Pharma board meetings
53 filed, newest first. Page 1 of 2.
Oct 2026
16 Oct · Board meeting
Meeting on 16 Oct 2026: preferential issue of shares
Sep 2026
Jul 2026
May 2026
22 May · Board meeting
Meeting on 28 May 2026: audited results and half yearly results5 May · Board meeting
Meeting on 5 May 2026: preferential issue of shares
Mar 2026
7 Mar · Board meeting
Nov 2025
17 Nov · Board meeting
Meeting on 17 Nov 2025: preferential issue of shares10 Nov · Board meeting
6 Nov · Board meeting
Meeting on 10 Nov 2025: half yearly results
Oct 2025
16 Oct · Board meeting
Meeting on 16 Oct 2025: preferential issue of shares16 Oct · Board meeting
3 Oct · Board meeting
1 Oct · Board meeting
Meeting on 1 Oct 2025: preferential issue of shares1 Oct · Board meeting
Sep 2025
2 Sep · Board meeting
Aug 2025
28 Aug · Board meeting
Meeting on 2 Sep 2025: annual general meeting and final dividend6 Aug · Board meeting
Jun 2025
24 Jun · Board meeting
Meeting on 26 Jun 2025: preferential issue of shares16 Jun · Board meeting
Meeting on 18 Jun 2025: issue of warrants and rights issue of equity shares
May 2025
26 May · Board meeting
Meeting on 29 May 2025: audited results
Feb 2025
24 Feb · Board meeting
Meeting on 24 Feb 2025
Jan 2025
3 Jan · Board meeting
Meeting on 8 Jan 2025: rights issue of equity shares
Oct 2024
24 Oct · Board meeting
Meeting on 30 Oct 2024: half yearly results
Sep 2024
4 Sep · Board meeting
Meeting on 7 Sep 2024: annual general meeting, final dividend and increase in authorised capital
Aug 2024
8 Aug · Board meeting
May 2024
17 May · Board meeting
Meeting on 24 May 2024: audited results